Eli Lilly and Co (NYSE:LLY) is evaluated against its competitors in the Pharmaceuticals industry, showing a mixed performance. While its PE, PB, and PS ratios suggest the stock might be overvalued, its high ROE and revenue growth indicate strong profitability and market share gain. However, concerns arise from its lower EBITDA and gross profit, alongside a higher debt-to-equity ratio compared to peers, signaling potential financial risks.